AstraZeneca’s Voydeya granted EC approval to treat rare blood disease PNH
AstraZeneca’s (AZ) Voydeya (danicopan) has been approved by the European Commission (EC) as an add-on therapy for adults with paroxysmal nocturnal haemoglobinuria (PNH). The oral factor D inhibitor has been authorised for use alongside AZ’s complement C5 …